Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting
Viruses · 31.10.2024 · 16 (11) · 1724
DOI: 10.3390/v16111724 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, online erschienen am 31.10.2024. Verfasst von Cristina Guadalupe Román López und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hospital Regional No. 1 "Ignacio García Tellez", Instituto Mexicano del Seguro Social, Mérida 97150, Yucatán, Mexico. Hauptthemen laut MEDLINE: Antiviral Agents, HIV Infections, Coinfection, Sustained Virologic Response. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Direct-acting antivirals (DAA) are effective in patients with hepatitis C virus (HCV) infection, but there is little information about real-world effectiveness in people living with human immunodeficiency virus (PLH). The aim of this study was to determinate the effectiveness of DAA to achieve sustained virologic response at week 12 post-treatment (SVR12) in PLH with HCV coinfection and in people with HCV-monoinfection. We conducted a prospective cohort. The full analysis set (FAS) included all subjects enrolled in the study; the modified analysis set (MAS) excluded cases with missing data to evaluate SVR12. A total of 278 people were included, 130 (46.7%) with HCV/HIV-coinfection and 148 (53.2%) with HCV-monoinfection. In the HCV/HIV-coinfection group, 82 (63%) received GLE/PIB for 8 weeks, 45 (34.6%) received SOF/VEL for 12 weeks, and 3 (2.3%) were treated with SOF/VEL + RBV for 12 weeks. In the HCV-monoinfection group, 62 (41.8%) received GLE/PIB for 8 weeks, 28 (18.9%) received SOF/VEL for 12 weeks, and 58 (39.1%) participants were treated with SOF/VEL + RBV for 12 weeks. In the FAS analysis, SVR12 was 81.6% in the HCV/HIV-coinfection group and 86.4% in the HCV-monoinfection group (p = 0.128). In the MAS analysis, both groups achieved 100% of SVR12. In this cohort, the effectiveness of DAA to achieve SVR12 was similar between HCV/HIV-coinfection and HCV-monoinfection cases, regardless of advanced liver disease with no differences between treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Hospital Regional No. 1 "Ignacio García Tellez", Instituto Mexicano del Seguro Social, Mérida 97150, Yucatán, Mexico.
- Infectious Diseases Department, Hospital de Infectologia "La Raza" National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico.
ORCID-Profile: Cristina Guadalupe Román López, Salma Triana González, Ana Luz Cano Díaz, José Antonio Mata Marín
Zitieren
APA
Román López, C. G., Triana González, S., Cano Díaz, A. L., Lopez, D. D. F., Mata Marín, J. A., & Gaytán Martínez, J. E. (2024). Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting. Viruses, 16(11), 1724. https://doi.org/10.3390/v16111724
Vancouver
Román López CG, Triana González S, Cano Díaz AL, Lopez DDF, Mata Marín JA, Gaytán Martínez JE. Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting. Viruses. 2024;16(11):1724. doi:10.3390/v16111724
BibTeX
@article{RomnLpez2024,
author = {Román López, Cristina Guadalupe and Triana González, Salma and Cano Díaz, Ana Luz and Lopez, Dulce Daniela Flores and Mata Marín, José Antonio and Gaytán Martínez, Jesús Enrique},
title = {Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting},
journal = {Viruses},
year = {2024},
volume = {16},
number = {11},
pages = {1724},
doi = {10.3390/v16111724}
}
EUVIMED